ArticleBMC infectious diseases2025
The contribution of TB rapid diagnostic testing in reducing TB-related mortality in Sub-Saharan Africa- in both Person-Living with HIV and HIV-Negative populations: A 9-year quantitative retrospective analysis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019-2024).BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA potential contributor to achieving WHO's "End-TB" goal of 90% reduction in TB related mortality by 2030, is scale-up of TB Rapid Diagnostic Testing (RDT). Our study evaluated the contribution of RDTs' in reducing TB-related mortality in both PLHIV and the HIV-negative population, from 2015 to 2023 in Sub-Saharan Africa (SSA).
methodsWe carried out an 9-year quantitative retrospective analysis of country-level data (annual WHO TB reports) for all countries in SSA reporting to the WHO. We estimated the following parameters: incidence, notification, percentage of undiagnosed TB patients, percentage diagnosis with RDTs, and TB-related mortality. We stratified the reports according to TB incidence (creating incidence strata) and limited further analysis to reports where the percentage of undiagnosed individuals was 30% or less. We then used scatter plots to examine the existence of a relationship between the use of RDTs and TB-related mortality, and quantified the observed relationships via linear regression models.
resultsOver the nine years, SSA made great strides toward the 2025 milestones of End-TB disease burden-related targets; TB disease incidence decreased by 14%; TB-related mortality decreased by 27.2%; and TB/HIV-related mortality decreased by 64.1%. Similarly, RDT became the priority TB disease diagnostic modality (66.0% in 2023). We found a consistent inverse relationship between RDT scale-up and TB-related mortality in the HIV-negative population, which was significantly stronger in the higher TB incidence settings (R2 = 0.692, P = 0.003). Following adjustments (R
conclusionsThis study provides support about the anticipated contributions of RDTs in decreasing TB-related mortality in SSA, highlighting the importance of maximum scaleup (addressing underdiagnosis of TB) and limiting the biased prioritization of PLHIV for these RDTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.